---
document_datetime: 2023-09-21 18:12:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/naglazyme-epar-procedural-steps-taken-authorisation_en.pdf
document_name: naglazyme-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3930541
conversion_datetime: 2025-12-26 13:48:42.996487
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant BioMarin Europe Ltd  submitted on 03 December 2004  an application for Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  through  the  centralised  procedure  for Naglazyme, which was designated as an orphan medicinal product EU/3/01/025 on 14 February 2001.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were:

Rapporteur:  Dr Ian Hudson

## Orphan Drugs:

Naglazyme was designated as an orphan medicinal product in the following indication:  Treatment of Mucopolysaccharidosis,  type  VI  (Maroteaux-Lamy  Syndrome).  The  calculated    prevalence  of  this condition was 0.024 per 10,000  EU population.

## Scientific Advice:

The applicant did not seek scientific advice at the CHMP.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 03 December 2004.
- The procedure started on 20 December 2004.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 1 March 2005 The  Co-Rapporteur's first Assessment  Report was  circulated  to  all  CHMP  members  on 07 March 2005
- During the meeting on 18-21 April 2005, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 21 April 2005
- The  applicant submitted the responses to the  CHMP  consolidated  List  of  Questions  on 20 May 2005.
- The  summary  report of the inspection carried out at the manufacturing site:  BioMarin Pharmaceuticals,  46  Galli  Drive,  Novato  USA,  between  20-24  June  2005  was  issued  on 21 July 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  01 July 2005
- During the CHMP meeting on 25-28 July 2005, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant .
- The  applicant  submitted  the  responses  to  the  CHMP  List  of  Outstanding  Issues  on  08  August 2005.
- During  the  meeting  on    12-15  September  2005  ,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation to Naglazyme on 15 September 2005. The applicant provided the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on 15 September 2005.
- The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the European Commission, which adopted the corresponding Decisions on 24 January 2006.

Co-Rapporteur:  Prof Beatriz Silva Lima